ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.5% – Here’s Why

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) shot up 4.5% on Tuesday. The stock traded as high as $6.38 and last traded at $6.2520. Approximately 1,757,559 shares were traded during trading, a decline of 91% from the average daily volume of 19,836,211 shares. The stock had previously closed at $5.98.

Wall Street Analysts Forecast Growth

IBRX has been the topic of a number of research analyst reports. Jefferies Financial Group raised their price target on ImmunityBio from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, October 14th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of ImmunityBio in a research note on Thursday, October 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Wall Street Zen lowered shares of ImmunityBio from a “hold” rating to a “sell” rating in a report on Saturday, November 14th. Finally, Piper Sandler reissued an “overweight” rating and issued a $16.00 target price on shares of ImmunityBio in a research report on Wednesday, October 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Check Out Our Latest Research Report on IBRX

ImmunityBio Trading Up 7.0%

The firm has a market capitalization of $7.13 billion, a price-to-earnings ratio of -6.20 and a beta of 0.17. The firm has a 50 day moving average price of $8.48 and a two-hundred day moving average price of $7.96.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of ImmunityBio stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the transaction, the director directly owned 100,309 shares of the company’s stock, valued at $1,053,244.50. The trade was a 44.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry Simon sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the transaction, the director directly owned 2,777,788 shares in the company, valued at approximately $29,861,221. This trade represents a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 66.10% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

Hedge funds and other institutional investors have recently made changes to their positions in the business. BlackRock Inc. raised its position in ImmunityBio by 29.4% in the second quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock valued at $298,399,000 after purchasing an additional 7,736,819 shares during the period. State Street Corp lifted its stake in shares of ImmunityBio by 20.8% during the second quarter. State Street Corp now owns 21,398,438 shares of the company’s stock worth $187,343,000 after purchasing an additional 3,690,335 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of ImmunityBio by 27.7% during the third quarter. Goldman Sachs Group Inc. now owns 4,129,906 shares of the company’s stock worth $38,986,000 after purchasing an additional 895,629 shares in the last quarter. Bank of America Corp DE purchased a new stake in shares of ImmunityBio in the second quarter worth about $19,125,000. Finally, Cetera Investment Advisers boosted its position in shares of ImmunityBio by 7.1% in the third quarter. Cetera Investment Advisers now owns 1,221,077 shares of the company’s stock worth $11,527,000 after buying an additional 80,601 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

About ImmunityBio

(Get Free Report)

ImmunityBio is a biotechnology company that develops immunotherapies for cancer and infectious diseases. Its research combines approaches including immune-modulating biologics, cell therapies and vaccine-based treatments, with a focus on activating the body’s natural and adaptive immune responses. The company’s lead product, Anktiva (nogapendekin alfa inbakicept-pmln), received U.S. Food and Drug Administration approval in 2024 for use with Bacillus Calmette-Guérin (BCG) in adults with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors.

See Also

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.